Phenylalanine hydroxylase mutant, recombinant strain and method for preparing 5-hydroxytryptophan

By constructing phenylalanine hydroxylase mutant and immobilized enzyme technology, the production efficiency and purification difficulty of 5-HTP are improved, and the problems of low production efficiency and difficulty of extraction in the existing technology are solved, and the problem of low production efficiency and high extraction difficulty of 5-HTP is achieved. Efficient and low-cost 5-HTP preparation.

CN118909987APending Publication Date: 2024-11-08HEBEI KAIENLI BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411090542.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing 5-HTP production methods have problems such as low yield, high extraction difficulty and high cost. In particular, the separation and extraction efficiency of 5-HTP in microbial fermentation methods is low and the by-products are difficult to control.

Method used

The isolation and purification process of the product was simplified by constructing the phenylalanine hydroxylase mutant, which increased the conversion rate of tryptophan and catalyzed the production of 5-HTP by immobilized enzymes.

Benefits of technology

It realizes efficient production of 5-HTP, with short reaction time, few by-products, and the tryptophan conversion rate reaches more than 95%, simplifying the separation and purification process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004986426040000161
    Figure BDA0004986426040000161
  • Figure BDA0004986426040000171
    Figure BDA0004986426040000171
Patent Text Reader

Abstract

The invention relates to the technical field of gene engineering, in particular to a phenylalanine hydroxylase mutant, a recombinant strain and a method for preparing 5-hydroxytryptophan. The phenylalanine hydroxylase mutant is obtained by mutation of one or more points in phenylalanine hydroxylase, and the mutation positions of the point mutation comprise K58G, Q117K, K230R and C265S; the amino acid sequence of the phenylalanine hydroxylase is as shown in SEQ ID No. 1. According to the phenylalanine hydroxylase mutant provided by the invention, the conversion rate of tryptophan is increased, the phenylalanine hydroxylase mutant is prepared into the immobilized enzyme, the immobilized enzyme is adopted to catalyze tryptophan to produce 5-HTP, the reaction time is short, few byproducts are produced, the product 5-HTP is easy to separate and purify, and the conversion rate of tryptophan reaches 95% or above.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of genetic engineering, and in particular to a phenylalanine hydroxylase mutant, a recombinant strain and a method for preparing 5-hydroxytryptophan. Background Art

[0002] As an over-the-counter drug, 5-HTP has been widely used in mental regulation drugs and weight loss nutritional products in developed countries such as Europe and the United States. The importance that the European and American markets attach to mental health determines the huge market demand for 5-HTP. At present, more than 40 types of health care drugs with 5-HTP as the main ingredient have been developed and marketed in 20 countries around the world, mainly in the form of capsules with a content of 100-150mg, but also in the form of tablets, powders and sustained-release preparations.

[0003] Tryptophan is one of the essential amino acids for the human body. It can be catalyzed by phenylalanine hydroxylase (PAH) in the body and converted into 5-hydroxytryptophan (5-HTP). 5-HTP is an amino acid substance with a chemical name of 5-hydroxy-3-indolyl-α-alanine and a molecular formula of C 11 H 12 N2O3, molecular weight is 220.23. 5-Hydroxytryptophan (5-HTP) is a natural amino acid that does not participate in protein synthesis. It is a derivative of tryptophan, which is generated by replacing the hydrogen atom at position 5 on the benzene ring of tryptophan with a hydroxyl group. In the human body, 5-Hydroxytryptophan is a precursor of the neurotransmitter serotonin and the amine hormone melatonin. It has a regulatory effect on physiological functions such as sleep, pain, body temperature, appetite and behavior, and has been used to treat depression, migraine and insomnia. When the serotonin content in the brain is reduced, supplementing 5-Hydroxytryptophan can increase the level of serotonin in the brain, which is more effective than supplementing L-tryptophan or directly supplementing serotonin. On the one hand, serotonin is synthesized by enterochromaffin cells, and serotonin cannot pass through the blood-brain barrier to enter the brain, and thus cannot supplement the brain's serotonin; on the other hand, about 98% of L-tryptophan in the blood is degraded into formylkynurenine by tryptophan monooxygenase. The increase in the concentration of formylkynurenine in the blood will also inhibit L-tryptophan from entering the central nervous system, thereby reducing the efficiency of L-tryptophan entering the central nervous system. 5-Hydroxytryptophan is an intermediate in the synthesis of serotonin from L-tryptophan. It does not participate in protein synthesis and other metabolic processes of the body, and is not degraded by tryptophan monooxygenase. It can easily cross the blood-brain barrier and enter the central nervous system without the need for carrier proteins. Compared with L-tryptophan, 5-Hydroxytryptophan can more specifically increase the level of serotonin in the brain.

[0004] Since 5-HTP has high medicinal health and market value, the production research of 5-HTP has developed rapidly in recent years. At present, commercial 5-HTP is mainly obtained through plant extraction and chemical synthesis. Since the raw material resources of plant extraction are scarce and the chemical synthesis method cannot solve the chirality problem, biosynthetic 5-HTP can make up for the above shortcomings, so it has a bright application prospect.

[0005] At present, the main methods for producing 5-HTP include natural product extraction, chemical synthesis and microbial fermentation. The first two methods have drawbacks that cannot be ignored. The low yield of the extraction method, easy to be affected by seasons, insufficient raw materials, and regional restrictions have become the main bottlenecks restricting large-scale production; the chemical method synthesis reaction system is relatively complex, the steps are cumbersome, the cost is high, and the control is difficult. Therefore, the microbial fermentation method has attracted great attention in the industry in recent years. Although the microbial fermentation method is low in cost and simple to operate, the separation and extraction of 5-HTP has always been a difficult problem in the industry. Due to the immaturity of fermentation, the yield of 5-HTP is low, the conventional extraction method has a low extraction yield, and the product loss is serious. The decomposition of the bacteria leads to an increase in soluble protein, which further increases the difficulty of separation and extraction. Fermentation byproducts headed by tryptophan are difficult to control, and the physical and chemical properties of tryptophan are extremely similar to those of 5-HTP, which has become the biggest difficulty in the separation and extraction of 5-HTP. Summary of the invention

[0006] In order to solve the above problems, the present invention provides a phenylalanine hydroxylase mutant, a recombinant strain and a method for preparing 5-hydroxytryptophan. The phenylalanine hydroxylase mutant provided by the present invention improves the conversion rate of tryptophan, is prepared into an immobilized enzyme, and the immobilized enzyme is used to catalyze the production of 5-HTP from tryptophan, which has the advantages of short reaction time, less by-products, easy separation and purification of the product 5-HTP, and the conversion rate of tryptophan reaches more than 95%.

[0007] In order to achieve the above object, the present invention provides the following technical solutions:

[0008] The present invention provides a phenylalanine hydroxylase mutant obtained by one or more point mutations in phenylalanine hydroxylase, wherein the mutation positions of the point mutations include:

[0009] K58G, Q117K, K230R and C265S;

[0010] The amino acid sequence of the phenylalanine hydroxylase is shown in SEQ ID No.1.

[0011] Preferably, when there are four point mutations at the same time, the point mutation positions include: K58G, Q117K, K230R and C265S.

[0012] The present invention provides a recombinant strain pET28a-PAH / BL21, which is constructed by the following construction method:

[0013] Connecting the gene encoding the phenylalanine hydroxylase mutant described in the above technical solution into pET-28a to obtain a recombinant vector;

[0014] The obtained recombinant vector was transformed into Escherichia coli BL21 (DE3) to obtain the recombinant strain pET28a-PAH / BL21 (DE3).

[0015] The present invention also provides a method for preparing 5-hydroxytryptophan, comprising the following steps:

[0016] 1) fermenting the recombinant strain pET28a-PAH / BL21(DE3) described in the above technical solution and collecting the bacterial cells;

[0017] 2) The bacterial cells obtained in step 1) are mixed with water and tryptophan and then transformed to obtain 5-hydroxytryptophan.

[0018] Preferably, the culture medium used in the fermentation in step 1) comprises: 10 g / L glucose, 11.5 g / L yeast extract, 15 g / L peptone, 4 g / L ammonium sulfate, 18 g / L dipotassium hydrogen phosphate, 3 g / L potassium dihydrogen phosphate and 1.2 g / L magnesium sulfate, pH 7.0;

[0019] The fermentation conditions include: a rotation speed of 170 rpm, culturing at 37° C. for 6 hours, adding isopropyl-β-D-thiogalactoside with a final concentration of 0.2 mM when the OD value reaches 0.6-0.8, and inducing expression at a temperature of 28° C. and 140 rpm for 20-28 hours.

[0020] Preferably, in step 2), the mass ratio of the bacteria to water and tryptophan is 10:100:0.2;

[0021] The transformation conditions include: temperature of 37° C. and time of 24 h.

[0022] The present invention also provides a method for preparing 5-hydroxytryptophan, comprising the following steps:

[0023] A. mixing an enzyme solution containing the phenylalanine hydroxylase mutant described in the above technical solution with a resin, and obtaining an immobilized enzyme after solid-liquid separation;

[0024] B. mixing the immobilized enzyme obtained in step A with tryptophan and tetrahydrobiopterin to obtain a reaction system;

[0025] C. reacting the reaction system obtained in step B to obtain 5-hydroxytryptophan.

[0026] Preferably, the enzyme activity concentration of the phenylalanine hydroxylase mutant in the enzyme solution of step A is 1350 U / L;

[0027] The mass ratio of enzyme activity in the enzyme solution to resin is 300U:1g, and the salt concentration of the enzyme solution is 1.2M;

[0028] The resin includes epoxy resin and / or amino resin, the model of the epoxy resin is ES-103B, and the model of the amino resin is ENK.

[0029] Preferably, the concentration of the immobilized enzyme in the reaction system of step B is 2.6 g / L, the concentration of tryptophan is 2 g / L, and the concentration of tetrahydrobiopterin is 0.01 g / L;

[0030] The pH value of the reaction system is 8.3.

[0031] Preferably, the reaction conditions of step C include: temperature of 13° C. and reaction time of 1 h.

[0032] Beneficial effects of the present invention:

[0033] The present invention uses the pah gene from Bacillus sonorensis to successfully construct the pET28a-PAH / BL21 production strain expressing PAH. The phenylalanine hydroxylase (PAH) has stable properties and can convert tryptophan into 5-HTP under the action of the coenzyme tetrahydrobiopterin (BH4). After microbial fermentation, cell disruption, protein extraction, purification and immobilization, the biological preparation of 5-HTP is finally achieved through the conversion of the immobilized enzyme.

[0034] The use of immobilized enzyme to catalyze the production of 5-HTP from tryptophan has the advantages of short reaction time, few by-products, and easy separation and purification of the product 5-HTP, making it the best choice for mass production of 5-HTP. DETAILED DESCRIPTION

[0035] The present invention provides a phenylalanine hydroxylase mutant, which is obtained by one or more point mutations in phenylalanine hydroxylase, wherein the mutation positions of the point mutations include: K58G, Q117K, K230R and C265S; the amino acid sequence of the phenylalanine hydroxylase is shown in SEQ ID No. 1. In the present invention, the nucleotide sequence encoding the phenylalanine hydroxylase is shown in SEQ ID No. 7.

[0036] SEQ ID No.1:

[0037] MTLDDKVPWFPRHISDLDKVSNSVLMYGKELDADHPGFKDKEYRKRMMFADIALNYKWGQQIPIVEYTEIEKTTWGRIYRELTRLYKTSACHEFQKNLGLLQDKAGYNEFDLPQLQVVSDFLKARTGFCLRPVAGYLSARDFLSGLAFRVFYCTQYIRHQADPFYTPEPDCCHELLGHVPMLADPKFARFSQEIGLASLGTSDEEIKKLATCYFFTIEFGLCRQDNQLKAYGAGLLSSVAELQHALSDKAVIKPFIPMKVINEECLVTTFQNGYFETSSFEDATRQMREFVRTIKRPFDVHYNPYTQSIEIIKTPKSVAKL;

[0038] SEQ ID No.7:

[0039] ATGACCCTGGATGATAAAGTTCCGTGGTTTCCGCGTCATATTTCAGATCTGGATAAAGTTAGCAATAGCGTGCTGATGTATGGCAAAGAACTGGATGCAGATCATCCGGGTTTTAAAGATAAAGAATATCGCAAACGTCGCATGATGTTTGCAGATATTGCACTGAACTATAAATGGGGTCAGCAGATTCCGATTGTGGAATATACCGAAATTGAAAAAACCACCTGGGGTCGTATTTATCGTGAACTGACCCGTCTGTATAAAACCAGCGCATGCCATGAATTTCAGAAAAATCTGGGTCTGCTGCAGGATAAAGCAGGCTATAATGAATTTGATCTGCCGCAGCTGCAGGTTGTTAGCGATTTCCTGAAAGCACGTACCGGTTTTTGTCTGCGTCCGGTTGCAGGTTATCTGAGCGCACGTGATTTTCTGAGCGGTCTGGCATTTCGTGTGTTTTATTGTACCCAGTATATTCGTCATCAGGCCGATCCGTTTTATACTCCGGAACCGGATTGTTGTCATGAACTGCTGGGTCATGTTCCGATGCTGGCAGATCCGAAATTTGCACGTTTTAGCCAAGAAATTGGTCTGGCAAGCCTGGGCACCAGTGATGAAGAAATCAAAAAACTGGCAACCTGCTACTTTTTCACCATTGAATTTGGTCTGTGCCGTCAGGATAATCAGCTGAAAGCATATGGTGCAGGTCTGCTGAGCAGCGTTGCAGAACTGCAGCATGCACTGAGCGATAAAGCCGTTATTAAACCGTTTATTCCGATGAAGGTGATCAACGAAGAATGTCTGGTTACCACCTTTCAGAATGGTTATTTCGAAACCAGCAGCTTTGAAGATGCAACCCGTCAGATGCGTGAATTTGTTCGTACCATTAAACGTCCGTTTGATGTGCATTATAATCCGTATACACAGAGCATCGAGATTATCAAAACCCCGAAAAGCGTTGCCAAACTG。

[0040] In the present invention, when only K58G occurs, the amino acid sequence of the phenylalanine hydroxylase mutant is shown as SEQ ID No.2, and the nucleotide sequence encoding the phenylalanine hydroxylase mutant is shown as SEQ ID No.8.

[0041] SEQ ID No.2:

[0042] MTLDDKVPWFPRHISDLDKVSNSVLMYGKELDADHPGFKDKEYRKRRMMFADIALNYGWGQQIPIVEYTEIEKTTWGRIYRELTRLYKTSACHEFQKNLGLLQDKAGYNEFDLPQLQVVSDFLKARTGFCLRPVAGYLSARDFLSGLAFRVFYCTQYIRHQ ADPFYTPEPDCCHELLGHVPMLADPKFARFSQEIGLASLGTSDEEIKKLATCYFFTIEFGLCRQDNQLKAYGAGLLSSVAELQHALSDKAVIKPFIPMKVINEECLVTTFQNGYFETSSSFEDATRQMREFVRTIKRPFDVHYNPYTQSIEIIKTPKSVAKL;

[0043] SEQ ID No.8:

[0044] ATGACCCTGGATGATAAAGTTCCGTGGTTTCCGCGTCATATTTCAGATCTGGATAAAGTTAGCAATAGCGTGCTGATGTATGGCAAAGAACTGGATGCAGATCATCCGGGTTTTAAAGATAAAGAATATCGCAAACGTCGCATGATGTTTGCAGATATTGCACTGAACTATGGGTGGGGTCAGCAGATTCCGATTGTGGAATATACCGAAATTGAAAAAACCACCTGGGGTCGTATTTATCGTGAACTGACCCGTCTGTATAAAACCAGCGCATGCCATGAATTTCAGAAAAATCTGGGTCTGCTGCAGGATAAAGCAGGCTATAATGAATTTGATCTGCCGCAGCTGCAGGTTGTTAGCGATTTCCTGAAAGCACGTACCGGTTTTTGTCTGCGTCCGGTTGCAGGTTATCTGAGCGCACGTGATTTTCTGAGCGGTCTGGCATTTCGTGTGTTTTATTGTACCCAGTATATTCGTCATCAGGCCGATCCGTTTTATACTCCGGAACCGGATTGTTGTCATGAACTGCTGGGTCATGTTCCGATGCTGGCAGATCCGAAATTTGCACGTTTTAGCCAAGAAATTGGTCTGGCAAGCCTGGGCACCAGTGATGAAGAAATCAAAAAACTGGCAACCTGCTACTTTTTCACCATTGAATTTGGTCTGTGCCGTCAGGATAATCAGCTGAAAGCATATGGTGCAGGTCTGCTGAGCAGCGTTGCAGAACTGCAGCATGCACTGAGCGATAAAGCCGTTATTAAACCGTTTATTCCGATGAAGGTGATCAACGAAGAATGTCTGGTTACCACCTTTCAGAATGGTTATTTCGAAACCAGCAGCTTTGAAGATGCAACCCGTCAGATGCGTGAATTTGTTCGTACCATTAAACGTCCGTTTGATGTGCATTATAATCCGTATACACAGAGCATCGAGATTATCAAAACCCCGAAAAGCGTTGCCAAACTG。

[0045] In the present invention, when only Q117K occurs, the amino acid sequence of the phenylalanine hydroxylase mutant is shown as SEQ ID No.3, and the nucleotide sequence encoding the phenylalanine hydroxylase mutant is shown as SEQ ID No.9.

[0046] SEQ ID No.3:

[0047] MTLDDKVPWFPRHISDLDKVSNSVLMYGKELDADHPGFKDKEYRKRRMMFADIALNYKWGQQIPIVEYTEIEKTTWGRIYRELTRLYKTSACHEFQKNLGLLQDKAGYNEFDLPQLKVVSDFLKARTGFCLRPVAGYLSARDFLSGLAFRVFYCTQYIRHQ ADPFYTPEPDCCHELLGHVPMLADPKFARFSQEIGLASLGTSDEEIKKLATCYFFTIEFGLCRQDNQLKAYGAGLLSSVAELQHALSDKAVIKPFIPMKVINEECLVTTFQNGYFETSSSFEDATRQMREFVRTIKRPFDVHYNPYTQSIEIIKTPKSVAKL;

[0048] SEQ ID No.9:

[0049] ATGACCCTGGATGATAAAGTTCCGTGGTTTCCGCGTCATATTTCAGATCTGGATAAAGTTAGCAATAGCGTGCTGATGTATGGCAAAGAACTGGATGCAGATCATCCGGGTTTTAAAGATAAAGAATATCGCAAACGTCGCATGATGTTTGCAGATATTGCACTGAACTATAAATGGGGTCAGCAGATTCCGATTGTGGAATATACCGAAATTGAAAAAACCACCTGGGGTCGTATTTATCGTGAACTGACCCGTCTGTATAAAACCAGCGCATGCCATGAATTTCAGAAAAATCTGGGTCTGCTGCAGGATAAAGCAGGCTATAATGAATTTGATCTGCCGCAGCTGAAAGTTGTTAGCGATTTCCTGAAAGCACGTACCGGTTTTTGTCTGCGTCCGGTTGCAGGTTATCTGAGCGCACGTGATTTTCTGAGCGGTCTGGCATTTCGTGTGTTTTATTGTACCCAGTATATTCGTCATCAGGCCGATCCGTTTTATACTCCGGAACCGGATTGTTGTCATGAACTGCTGGGTCATGTTCCGATGCTGGCAGATCCGAAATTTGCACGTTTTAGCCAAGAAATTGGTCTGGCAAGCCTGGGCACCAGTGATGAAGAAATCAAAAAACTGGCAACCTGCTACTTTTTCACCATTGAATTTGGTCTGTGCCGTCAGGATAATCAGCTGAAAGCATATGGTGCAGGTCTGCTGAGCAGCGTTGCAGAACTGCAGCATGCACTGAGCGATAAAGCCGTTATTAAACCGTTTATTCCGATGAAGGTGATCAACGAAGAATGTCTGGTTACCACCTTTCAGAATGGTTATTTCGAAACCAGCAGCTTTGAAGATGCAACCCGTCAGATGCGTGAATTTGTTCGTACCATTAAACGTCCGTTTGATGTGCATTATAATCCGTATACACAGAGCATCGAGATTATCAAAACCCCGAAAAGCGTTGCCAAACTG。

[0050] In the present invention, when only K230R occurs, the amino acid sequence of the phenylalanine hydroxylase mutant is shown as SEQ ID No.4, and the nucleotide sequence encoding the phenylalanine hydroxylase mutant is shown as SEQ ID No.10.

[0051] SEQ ID No.4:

[0052] MTLDDKVPWFPRHISDLDKVSNSVLMYGKELDADHPGFKDKEYRKRRMMFADIALNYKWGQQIPIVEYTEIEKTTWGRIYRELTRLYKTSACHEFQKNLGLLQDKAGYNEFDLPQLQVVSDFLKARTGFCLRPVAGYLSARDFLSGLAFRVFYCTQYIRHQ ADPFYTPEPDCCHELLGHVPMLADPKFARFSQEIGLASLGTSDEEIKKLATCYFFTIEFGLCRQDNQLRAYGAGLLSSVAELQHALSDKAVIKPFIPMKVINEECLVTTFQNGYFETSSSFEDATRQMREFVRTIKRPFDVHYNPYTQSIEIIKTPKSVAKL;

[0053] SEQ ID No.10:

[0054] ATGACCCTGGATGATAAAGTTCCGTGGTTTCCGCGTCATATTTCAGATCTGGATAAAGTTAGCAATAGCGTGCTGATGTATGGCAAAGAACTGGATGCAGATCATCCGGGTTTTAAAGATAAAGAATATCGCAAACGTCGCATGATGTTTGCAGATATTGCACTGAACTATAAATGGGGTCAGCAGATTCCGATTGTGGAATATACCGAAATTGAAAAAACCACCTGGGGTCGTATTTATCGTGAACTGACCCGTCTGTATAAAACCAGCGCATGCCATGAATTTCAGAAAAATCTGGGTCTGCTGCAGGATAAAGCAGGCTATAATGAATTTGATCTGCCGCAGCTGCAGGTTGTTAGCGATTTCCTGAAAGCACGTACCGGTTTTTGTCTGCGTCCGGTTGCAGGTTATCTGAGCGCACGTGATTTTCTGAGCGGTCTGGCATTTCGTGTGTTTTATTGTACCCAGTATATTCGTCATCAGGCCGATCCGTTTTATACTCCGGAACCGGATTGTTGTCATGAACTGCTGGGTCATGTTCCGATGCTGGCAGATCCGAAATTTGCACGTTTTAGCCAAGAAATTGGTCTGGCAAGCCTGGGCACCAGTGATGAAGAAATCAAAAAACTGGCAACCTGCTACTTTTTCACCATTGAATTTGGTCTGTGCCGTCAGGATAATCAGCTGAGGGCATATGGTGCAGGTCTGCTGAGCAGCGTTGCAGAACTGCAGCATGCACTGAGCGATAAAGCCGTTATTAAACCGTTTATTCCGATGAAGGTGATCAACGAAGAATGTCTGGTTACCACCTTTCAGAATGGTTATTTCGAAACCAGCAGCTTTGAAGATGCAACCCGTCAGATGCGTGAATTTGTTCGTACCATTAAACGTCCGTTTGATGTGCATTATAATCCGTATACACAGAGCATCGAGATTATCAAAACCCCGAAAAGCGTTGCCAAACTG。

[0055] In the present invention, when only C265S occurs, the amino acid sequence of the phenylalanine hydroxylase mutant is shown as SEQ ID No.5, and the nucleotide sequence encoding the phenylalanine hydroxylase mutant is shown as SEQ ID No.11.

[0056] SEQ ID No.5:

[0057] MTLDDKVPWFPRHISDLDKVSNSVLMYGKELDADHPGFKDKEYRKRRMMFADIALNYKWGQQIPIVEYTEIEKTTWGRIYRELTRLYKTSACHEFQKNLGLLQDKAGYNEFDLPQLQVVSDFLKARTGFCLRPVAGYLSARDFLSGLAFRVFYCTQYIRHQ ADPFYTPEPDCCHELLGHVPMLADPKFARFSQEIGLASLGTSDEEIKKLATCYFFTIEFGLCRQDNQLKAYGAGLLSSVAELQHALSDKAVIKPFIPMKVINEESLVTTFQNGYFETSSSFEDATRQMREFVRTIKRPFDVHYNPYTQSIEIIKTPKSVAKL;

[0058] SEQ ID No.11:

[0059] ATGACCCTGGATGATAAAGTTCCGTGGTTTCCGCGTCATATTTCAGATCTGGATAAAGTTAGCAATAGCGTGCTGATGTATGGCAAAGAACTGGATGCAGATCATCCGGGTTTTAAAGATAAAGAATATCGCAAACGTCGCATGATGTTTGCAGATATTGCACTGAACTATAAATGGGGTCAGCAGATTCCGATTGTGGAATATACCGAAATTGAAAAAACCACCTGGGGTCGTATTTATCGTGAACTGACCCGTCTGTATAAAACCAGCGCATGCCATGAATTTCAGAAAAATCTGGGTCTGCTGCAGGATAAAGCAGGCTATAATGAATTTGATCTGCCGCAGCTGCAGGTTGTTAGCGATTTCCTGAAAGCACGTACCGGTTTTTGTCTGCGTCCGGTTGCAGGTTATCTGAGCGCACGTGATTTTCTGAGCGGTCTGGCATTTCGTGTGTTTTATTGTACCCAGTATATTCGTCATCAGGCCGATCCGTTTTATACTCCGGAACCGGATTGTTGTCATGAACTGCTGGGTCATGTTCCGATGCTGGCAGATCCGAAATTTGCACGTTTTAGCCAAGAAATTGGTCTGGCAAGCCTGGGCACCAGTGATGAAGAAATCAAAAAACTGGCAACCTGCTACTTTTTCACCATTGAATTTGGTCTGTGCCGTCAGGATAATCAGCTGAAAGCATATGGTGCAGGTCTGCTGAGCAGCGTTGCAGAACTGCAGCATGCACTGAGCGATAAAGCCGTTATTAAACCGTTTATTCCGATGAAGGTGATCAACGAAGAAAGTCTGGTTACCACCTTTCAGAATGGTTATTTCGAAACCAGCAGCTTTGAAGATGCAACCCGTCAGATGCGTGAATTTGTTCGTACCATTAAACGTCCGTTTGATGTGCATTATAATCCGTATACACAGAGCATCGAGATTATCAAAACCCCGAAAAGCGTTGCCAAACTG。

[0060] In the present invention, when K58G, Q117K, K230R and C265S occur simultaneously, the amino acid sequence of the phenylalanine hydroxylase mutant is shown as SEQ ID No.6, and the nucleotide sequence encoding the phenylalanine hydroxylase mutant is shown as SEQ ID No.12.

[0061] SEQ ID No.6:

[0062] MTLDDKVPWFPRHISDLDKVSNSVLMYGKELDADHPGFKDKEYRKRRMMFADIALNYGWGQQIPIVEYTEIEKTTWGRIYRELTRLYKTSACHEFQKNLGLLQDKAGYNEFDLPQLKVVSDFLKARTGFCLRPVAGYLSARDFLSGLAFRVFYCTQYIRHQ ADPFYTPEPDCCHELLGHVPMLADPKFARFSQEIGLASLGTSDEEIKKLATCYFFTIEFGLCRQDNQLRAYGAGLLSSVAELQHALSDKAVIKPFIPMKVINEESLVTTFQNGYFETSSSFEDATRQMREFVRTIKRPFDVHYNPYTQSIEIIKTPKSVAKL.

[0063] SEQ ID No.12:

[0064] ATGACCCTGGATGATAAAGTTCCGTGGTTTCCGCGTCATATTTCAGATCTGGATAAAGTTAGCAATAGCGTGCTGATGTATGGCAAAGAACTGGATGCAGATCATCCGGGTTTTAAAGATAAAGAATATCGCAAACGTCGCATGATGTTTGCAGATATTGCACTGAACTATGGGTGGGGTCAGCAGATTCCGATTGTGGAATATACCGAAATTGAAAAAACCACCTGGGGTCGTATTTATCGTGAACTGACCCGTCTGTATAAAACCAGCGCATGCCATGAATTTCAGAAAAATCTGGGTCTGCTGCAGGATAAAGCAGGCTATAATGAATTTGATCTGCCGCAGCTGAAAGTTGTTAGCGATTTCCTGAAAGCACGTACCGGTTTTTGTCTGCGTCCGGTTGCAGGTTATCTGAGCGCACGTGATTTTCTGAGCGGTCTGGCATTTCGTGTGTTTTATTGTACCCAGTATATTCGTCATCAGGCCGATCCGTTTTATACTCCGGAACCGGATTGTTGTCATGAACTGCTGGGTCATGTTCCGATGCTGGCAGATCCGAAATTTGCACGTTTTAGCCAAGAAATTGGTCTGGCAAGCCTGGGCACCAGTGATGAAGAAATCAAAAAACTGGCAACCTGCTACTTTTTCACCATTGAATTTGGTCTGTGCCGTCAGGATAATCAGCTGAGGGCATATGGTGCAGGTCTGCTGAGCAGCGTTGCAGAACTGCAGCATGCACTGAGCGATAAAGCCGTTATTAAACCGTTTATTCCGATGAAGGTGATCAACGAAGAAAGTCTGGTTACCACCTTTCAGAATGGTTATTTCGAAACCAGCAGCTTTGAAGATGCAACCCGTCAGATGCGTGAATTTGTTCGTACCATTAAACGTCCGTTTGATGTGCATTATAATCCGTATACACAGAGCATCGAGATTATCAAAACCCCGAAAAGCGTTGCCAAACTG。

[0065] The present invention also provides a recombinant strain pET28a-PAH / BL21, which is constructed by the following construction method: connecting the gene encoding the phenylalanine hydroxylase mutant described in the above technical solution to pET-28a to obtain a recombinant vector; and transferring the obtained recombinant vector into Escherichia coli BL21 to obtain the recombinant strain pET28a-PAH / BL21. The present invention does not specifically limit the construction method of the recombinant strain pET28a-PAH / BL21, and those skilled in the art can construct it using conventional construction methods.

[0066] The present invention provides a method for preparing 5-hydroxytryptophan, comprising the following steps:

[0067] 1) fermenting the recombinant strain pET28a-PAH / BL21 described in the above technical solution and collecting the bacterial cells;

[0068] 2) The bacterial cells obtained in step 1) are mixed with water and tryptophan and then transformed to obtain 5-hydroxytryptophan.

[0069] The present invention ferments the recombinant strain pET28a-PAH / BL21 described in the above technical scheme and collects the bacterial cells. In the present invention, the culture medium used for the fermentation preferably includes: 10g / L glucose, 11.5g / L yeast extract, 15g / L peptone, 4g / L ammonium sulfate, 18g / L dipotassium hydrogen phosphate, 3g / L potassium dihydrogen phosphate and 1.2g / L magnesium sulfate, pH 7.0. In the present invention, the fermentation conditions preferably include: a rotation speed of 170rpm, culturing at 37°C for 6h, and when the OD value reaches 0.6-0.8, adding isopropyl-β-D-thiogalactoside at a final concentration of 0.2mM, and inducing expression at a temperature of 28°C and 140rpm for 20-28h.

[0070] The present invention converts the obtained bacterial cells into 5-hydroxytryptophan after mixing with water and tryptophan. In the present invention, the mass ratio of the bacterial cells to water and tryptophan is preferably 10:100:0.2. In the present invention, the conversion conditions preferably include: a temperature of 37°C and a time of 24h.

[0071] The present invention provides a method for preparing 5-hydroxytryptophan, comprising the following steps:

[0072] A. mixing an enzyme solution containing the phenylalanine hydroxylase mutant described in the above technical solution with a resin, and obtaining an immobilized enzyme after solid-liquid separation;

[0073] B. mixing the immobilized enzyme obtained in step A with tryptophan and tetrahydrobiopterin to obtain a reaction system;

[0074] C. reacting the reaction system obtained in step B to obtain 5-hydroxytryptophan.

[0075] The present invention mixes the enzyme solution containing the phenylalanine hydroxylase mutant described in the above technical solution with a resin, and obtains an immobilized enzyme after solid-liquid separation. In the present invention, the enzyme activity concentration of the phenylalanine hydroxylase mutant in the enzyme solution is preferably 1350U / L. In the present invention, the mass ratio of the enzyme activity in the enzyme solution to the resin is 300U:1g, and the salt concentration of the enzyme solution is 1.2M. Immobilization requires a certain salt concentration, and the salt concentration of the liquid enzyme needs to be adjusted to 1.2M with phosphate so that it can be fixed to the resin carrier. In the present invention, the resin is preferably an epoxy resin, the model of the epoxy resin is ES-103B, and the model of the amino resin is ENK.

[0076] The present invention mixes the obtained immobilized enzyme with tryptophan and tetrahydrobiopterin to obtain a reaction system. In the present invention, the concentration of the immobilized enzyme in the reaction system is preferably 2.6 g / L, the concentration of tryptophan is preferably 2 g / L, the concentration of tetrahydrobiopterin is preferably 0.01 g / L, and the tetrahydrobiopterin accelerates the reaction speed. In the present invention, the pH value of the reaction system is preferably 8.3.

[0077] The present invention conducts a reaction on the obtained reaction system to obtain 5-hydroxytryptophan. In the present invention, the reaction conditions preferably include: a temperature of 13° C. and a reaction time of 1 hour.

[0078] In order to further illustrate the present invention, the present invention is described in detail below in conjunction with embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0079] Reagents and instruments of the embodiment:

[0080] 1. Reagent Configuration

[0081] 1. Culture medium configuration

[0082] LB liquid medium: 10 g / L peptone, 5 g / L yeast extract, 10 g / L sodium chloride.

[0083] LB solid medium: 10 g / L peptone, 5 g / L yeast extract, 10 g / L sodium chloride, 16 g / L agar powder.

[0084] Fermentation medium: 2g / L yeast powder, 10g / L glucose, 6g / L disodium hydrogen phosphate, 5g / L sodium chloride, 3g / L potassium dihydrogen phosphate, 246.5mg / L magnesium sulfate heptahydrate, 27.8mg / L ferrous sulfate heptahydrate, 2g / L dipotassium hydrogen phosphate.

[0085] The above culture media were sterilized by wet heat sterilization at 122°C for 30 min. Glucose was sterilized by wet heat sterilization at 115°C for 30 min and then added to the corresponding culture media.

[0086] 1g / L kanamycin (Kanamycin, Kan), kanamycin needs to be filtered and sterilized.

[0087] 2. Configuration of biochemical reagents

[0088] 5xSDS Loading Buffer: 250mMTris-HCl (pH6.8), 10% (W / V) SDS, 0.5% (W / V) bromophenol blue, 50% (V / V) glycerol, 5% (V / V) β-mercaptoethanol. Dissolve the above components, except β-mercaptoethanol, adjust the pH, make up to volume, dispense 1mL / tube and store at -20℃. Add 50μL β-mercaptoethanol and mix before use. Store the Loading Buffer with β-mercaptoethanol in a 4℃ refrigerator.

[0089] 5xSDS Tris-Glycine Buffer (SDS-PAGE electrophoresis buffer): 0.125M Tris-HCl (pH 8.0), 1.25M glycine, 0.5% (W / V) SDS.

[0090] SDS-PAGE staining solution: 100 mL methanol, 20 mL acetic acid, 0.2 g Coomassie Brilliant Blue R-250, add water to 200 mL.

[0091] SDS-PAGE decolorizing solution: 300 mL methanol, 100 mL acetic acid, add water to 1000 mL.

[0092] 50xTAEBuffer (nucleic acid electrophoresis buffer): 242g Tris, 37.2g Na2EDTA·2H2O, add about 800mL of purified water to dissolve, add 57.1mL of acetic acid, and dilute to 1000mL with purified water.

[0093] 1% agarose gel: weigh 1g agarose, add 100mL 1xTAE buffer, heat to boiling on an electric stove, boil three times to dissolve the agarose completely, lower the temperature to about 60°C, add 2μL DNAgreen nucleic acid dye, pour into a gel mold, and cool until solidified.

[0094] 2. Preparation of pET28a-PAH / BL21(DE3)

[0095] 1. Preparation of heat shock competent Escherichia coli

[0096] (1) Take out BL21(DE3) from a -20℃ or -80℃ freezer, dilute and spread on or streak LB solid plates, and incubate in a 37℃ incubator for 16 to 24 hours.

[0097] (2) Pick a single colony and inoculate 20 mL of LB liquid medium. Culture overnight at 37°C and 140 rpm.

[0098] (3) Take 1 mL of culture medium and inoculate 100 mL of LB liquid medium. Cultivate at 37°C and 140 rpm until OD600 = 0.5-0.6. Place on ice for 10 min.

[0099] (4) Divide the culture medium after ice bath into two 50 mL centrifuge tubes and centrifuge at 4500 rpm, 4°C for 5 min.

[0100] (5) Pour off the supernatant and gently resuspend each tube of cells in 30 mL of ice-cold 0.1 mol CaCl2 solution. Centrifuge at 3000 rpm, 4°C for 5 min.

[0101] (6) Pour off the supernatant and gently resuspend each tube of cells in 30 mL of ice-cold 0.1 mol CaCl2 solution. Place on ice for 30 min. Centrifuge at 3000 rpm, 4°C for 5 min.

[0102] (7) Pour off the supernatant and add 2 mL of ice-cold 15% glycerol + 0.1 mol CaCl2 solution to each tube of cells to gently resuspend them. Divide the cells into sterile 1.5 mL centrifuge tubes, 100 μL / tube, and store at -80°C.

[0103] 2. Transformation of heat-shock competent E. coli

[0104] (1) Take out the frozen BL21(DE3) E. coli competent cells from the -80℃ freezer and place them on ice for 5 minutes.

[0105] (2) Add 4 μL of plasmid (extracted using SanPrep column-based plasmid DNA minipreparation kit), mix gently, and place on ice for 30 min.

[0106] (3) Heat shock the cells in a 42°C water bath for 90 seconds and place them on ice for 2 minutes to avoid shaking the competent cells.

[0107] (4) Add 800 μL LB liquid culture medium (without adding resistance) and incubate at 37°C, 140 rpm for 1 hour for recovery.

[0108] (5) Take 100 μL of the culture solution and spread it on a kanamycin-resistant LB solid plate medium.

[0109] (6) Incubate the cells upside down in a 37°C incubator overnight.

[0110] (7) Use an inoculation needle to pick up the successfully transformed transformants and place them in 20 mL of LB liquid medium, and add kanamycin at a final concentration of 50 mg / L. Incubate at 37°C and 140 rpm.

[0111] 3. Determination of tryptophan and 5-HTP content:

[0112] The results were determined by high performance liquid chromatography analysis system.

[0113] Chromatographic separation conditions: Agilent C18 (4.6 mm×150 mm, 5 μm), mobile phase V (0.3% KH2PO4 solution): V (methanol) = 95:5, flow rate 1 mL / min, detection wavelength 276 m. Column temperature: 25°C.

[0114] Sample preparation: Weigh 15 mg and dissolve in a 50 ml volumetric flask, dissolve in methanol, and filter through a 0.45 μm membrane.

[0115] Preparation of standard sample: weigh 10 mg and dissolve in a 25 mL volumetric flask, dissolve in methanol, and filter through a 0.45 μm membrane.

[0116] 4. Materials and Methods

[0117] 1. Instruments and reagents

[0118] 1.1 Instruments: Refrigerated centrifuge (Suzhou Well); nucleic acid electrophoresis instrument (Beijing Liuyi), vertical electrophoresis instrument (Shenggong Biotechnology); ultrasonic cell disruptor (Ningbo Xinzhi); constant temperature oscillator (Suzhou Well).

[0119] 1.2 Main reagents: pET-28a; T4 DNA ligase and restriction endonucleases EcoRI and Xho I; IPTG (isopropyl-β-D-thiogalactopyranoside, Tianmen Hengchang); DH5α competent cells; BL21 (DE3) competent cells; SanPrep column plasmid DNA small-scale extraction kit; agarose gel; DNA recovery kit; Coomassie Brilliant Blue G-250. Primer synthesis and sequencing in the experiment were completed by Sangon Biotechnology (Shanghai).

[0120] 2 Methods

[0121] 2.1 Construction and verification of recombinant expression plasmid pET28a-PAH:

[0122] The PAH gene was connected to the vector pET28a to construct the recombinant plasmid pET28a-PAH. Six positive clones were selected for colony PCR identification. Agarose gel electrophoresis showed that the PCR product size was about 1700 bp, which was consistent with the size of the PAH gene. At the same time, the plasmid of the positive clone was extracted and double-digested with EcoRI and Xho I to obtain a pET28a linear fragment of about 6000 bp and an insert fragment of about 1700 bp. The above results all indicate that the recombinant plasmid pET28a-PAH was successfully constructed.

[0123] 2.2 Detection of 5-HTP:

[0124] Detection of 5-HTP: 5-HTP was detected by high-performance liquid chromatography. Agilent C18 (4.6 mm × 150 mm, 5 μm), mobile phase V (0.3% KH2PO4 solution): V (methanol) = 95:5, flow rate 1 mL / min, detection wavelength 276 m. Column temperature: 25°C; flow rate 1 ml / min; injection volume 10 μl.

[0125] Example 1

[0126] Phenylalanine hydroxylase mutants, obtained by point mutations of phenylalanine hydroxylase, the mutation positions of point mutations are: K58G, Q117K, K230R and C265S;

[0127] The amino acid sequence of phenylalanine hydroxylase is shown in SEQ ID No. 1, and the nucleotide sequence is shown in SEQ ID No. 7;

[0128] When only K58G occurs, the amino acid sequence of the phenylalanine hydroxylase mutant is shown in SEQ ID No. 2, and the nucleotide sequence encoding the phenylalanine hydroxylase mutant is shown in SEQ ID No. 8;

[0129] When only Q117K occurs, the amino acid sequence of the phenylalanine hydroxylase mutant is shown in SEQ ID No. 3, and the nucleotide sequence encoding the phenylalanine hydroxylase mutant is shown in SEQ ID No. 9;

[0130] When only K230R occurs, the amino acid sequence of the phenylalanine hydroxylase mutant is shown in SEQ ID No. 4, and the nucleotide sequence encoding the phenylalanine hydroxylase mutant is shown in SEQ ID No. 10;

[0131] When only C265S occurs, the amino acid sequence of the phenylalanine hydroxylase mutant is shown in SEQ ID No. 5, and the nucleotide sequence encoding the phenylalanine hydroxylase mutant is shown in SEQ ID No. 11;

[0132] When K58G, Q117K, K230R and C265S occur simultaneously, the amino acid sequence of the phenylalanine hydroxylase mutant is shown as SEQ ID No.6, and the nucleotide sequence encoding the phenylalanine hydroxylase mutant is shown as SEQ ID No.12.

[0133] Construction method of recombinant strain:

[0134] 1. Preparation of heat shock competent Escherichia coli

[0135] (1) Take out BL21(DE3) from a -20℃ or -80℃ freezer, dilute and spread on or streak LB solid plates, and incubate in a 37℃ incubator for 16 to 24 hours.

[0136] (2) Pick a single colony and inoculate 20 mL of LB liquid medium. Culture overnight at 37°C and 140 rpm.

[0137] (3) Take 1 mL of culture medium and inoculate 100 mL of LB liquid medium. Cultivate at 37°C and 140 rpm until OD600 = 0.5-0.6. Place on ice for 10 min.

[0138] (4) Divide the culture medium after ice bath into two 50 mL centrifuge tubes and centrifuge at 4500 rpm, 4°C for 5 min.

[0139] (5) Pour off the supernatant and gently resuspend each tube of cells in 30 mL of ice-cold 0.1 mol CaCl2 solution. Centrifuge at 3000 rpm, 4°C for 5 min.

[0140] (6) Pour off the supernatant and gently resuspend each tube of cells in 30 mL of ice-cold 0.1 mol CaCl2 solution. Place on ice for 30 min. Centrifuge at 3000 rpm, 4°C for 5 min.

[0141] (7) Pour off the supernatant and add 2 mL of ice-cold 15% glycerol + 0.1 mol CaCl2 solution to each tube of cells to gently resuspend them. Divide the cells into sterile 1.5 mL centrifuge tubes, 100 μL / tube, and store at -80°C.

[0142] 2. Transformation of heat-shock competent E. coli

[0143] (1) Take out the frozen BL21(DE3) E. coli competent cells from the -80℃ freezer and place them on ice for 5 minutes.

[0144] (2) Add 4 μL of plasmid (extracted using SanPrep column-based plasmid DNA minipreparation kit), mix gently, and place on ice for 30 min.

[0145] (3) Heat shock the cells in a 42°C water bath for 90 seconds, then remove them from the water and place them on ice for 2 minutes to avoid shaking the competent cells.

[0146] (4) Add 800 μL LB liquid culture medium (without adding resistance) and incubate at 37°C, 140 rpm for 1 hour for recovery.

[0147] (5) Take 100 μL of the culture solution and spread it on a kanamycin-resistant LB solid plate medium.

[0148] (6) Incubate the cells upside down in a 37°C incubator overnight.

[0149] (7) Use an inoculation needle to pick up the successfully transformed transformants and place them in 20 mL LB liquid medium, and add kanamycin at a final concentration of 50 mg / L. Incubate at 37°C and 140 rpm.

[0150] Preparation of wet bacteria of strain pET28a-PAH / BL21(DE3):

[0151] (1) Activation culture: The pET28a-PAH / BL21 (DE3) strain stored in a glycerol tube at -80°C was inoculated into LB medium and cultured at 37°C for 16 hours: the activation medium formula is: peptone 1 g / L, yeast powder 0.5 g / L, sodium chloride 1 g / L, solvent is water, pH 6.0.

[0152] (2) Seed culture: pick a loop of the bacteria obtained in step (1) with an inoculation loop, inoculate it into a seed culture medium, and culture it at a constant temperature of 37°C at a shaking speed of 170 rpm for 12 hours to obtain a seed solution; the formula of the seed culture medium is: peptone 1 g / L, yeast powder 1 g / L, glucose 5 g / L, potassium dihydrogen phosphate 1 g / L, MgSO4 0.1 g / L, CaCl2 0.1 g / L, FeCl3 0.02 g / L, the solvent is water, pH 6.8.

[0153] (3) Fermentation culture: The seed solution obtained in step (2) was inoculated into the fermentation medium at an inoculum volume of 1%, and cultured at 37° C. for 6 h at a shaking table with a rotation speed of 170 rpm. When the OD value reached 0.8, IPTG with a final concentration of 0.2 mM was added, and the expression was induced at 28° C. and 140 rpm for 24 h. The formula of the fermentation medium is: 10 g / L glucose, 11.5 g / L yeast extract, 15 g / L peptone, 4 g / L ammonium sulfate, 18 g / L dipotassium hydrogen phosphate, 3 g / L potassium dihydrogen phosphate, 1.2 g / L magnesium sulfate, pH 7.0.

[0154] (4) Centrifuge the fermentation broth at 4500 rpm for 15 min to collect the wet cells for later use.

[0155] Preparation of 5-HTP:

[0156] 100 mL of purified water containing 10 g of wet bacteria and 0.2 g of substrate tryptophan was added to the transformation bottle, and the reaction was carried out at 37°C for 24 h. After the reaction was completed, the supernatant was centrifuged to obtain a reaction solution containing 5-HTP. The supernatant was filtered with a 0.45 μm microfiltration membrane, and the filtrate was detected with a high performance liquid chromatograph.

[0157] Table 15 - Validation results of HTP mutants

[0158]

[0159] Example 2

[0160] Liquid enzyme preparation of 5-HTP:

[0161] The preparation of wet bacteria (i.e., wild type) is the same as in Example 1. 100 mL of phosphate buffer solution (pH 7.0, 0.07 M) containing wet bacteria with a total OD of 150 and 0.2 g of substrate tryptophan was added to the transformation bottle. The transformation was carried out at 37° C. for 24 h. After the reaction was completed, the supernatant was centrifuged to obtain a reaction solution containing 5-HTP. The supernatant was filtered with a 0.45 μm microfiltration membrane, and the filtrate was detected with a high performance liquid chromatograph. The 5-HTP content was 0.168 g, and the substrate conversion rate was 78%.

[0162] Example 3

[0163] Preparation of immobilized enzyme:

[0164] The strain pET28a-PAH / BL21(DE3) was activated on LB solid medium and cultured overnight at 37°C. A single clone was picked and inoculated into 20 ml LB medium (containing 50 mg / L kanamycin). After overnight culture in a constant temperature shaker (37°C, 170 r / min), all were transferred to 100 ml fermentation medium and cultured in a 500 ml conical flask in a constant temperature shaker (37°C, 170 r / min) until OD 600 After the pH value is 0.6-0.8, IPTG is added to a final concentration of 0.2 mmol / L. After continued induction in a constant temperature shaker (28°C, 140 r / min) for 48 h, the bacteria are collected by centrifugation at 4500 r / min for 10 min, resuspended in 50 ml of phosphate buffered saline (pH 7.5), and ultrasonically disrupted with an ultrasonic disruptor in an ice bath. After the cells are broken, a flocculant at 0.45% of the volume of the enzyme solution is added for flocculation, the bacterial residue is removed by centrifugation, the protein solution is collected, and then the protein solution is purified to obtain the enzyme solution before immobilization; the resin is then pre-activated and activated (pre-activation: soaking in 0.02M phosphate buffer for 1.5h; activation: treatment with an activation solution with a mass percentage of 2.5% glutaraldehyde for 1.5h) (the component is 0.02M phosphate buffer, and then adding glutaraldehyde with a final mass concentration of 2.5%, pH8.00, as the activation solution), and finally the treated enzyme solution is added to the activated resin (the enzyme activity unit of the enzyme solution is U, 1 gram of resin is added at a ratio of 300U), stirring is started, the temperature is raised to 25°C, and stirring is carried out for 60h, the finished product is separated from the enzyme solution, the finished product is washed three times with water, and then soaked in 1% sodium glutamate for 4h, and finally washed clean with water to obtain the immobilized enzyme, and soaked in 1M phosphate buffer for preservation and standby use.

[0165] The enzyme reaction system is: tryptophan 2g / L, BH4 0.01 g / L, add 0.3 times the weight of tryptophan solid enzyme, temperature 13°C, pH value 8.3. After 1 hour of reaction, start to take the reaction supernatant, dilute 100 times into the liquid phase to detect the amount of 5-HTP generated and the residual tryptophan.

[0166] Table 2 Validation of immobilized enzyme using 6 amino acid sequence combination mutants

[0167]

[0168] Verification of immobilized enzyme showed that the conversion rate of epoxy resin was significantly higher than that of amino carrier, but the conversion rate of amino carrier was increased by a higher multiple after gene mutation, which needs further verification.

[0169] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A phenylalanine hydroxylase mutant, It is characterized in that Obtained by one or more point mutations in phenylalanine hydroxylase, the mutation positions of the point mutations include: K58G, Q117K, K230R and C265S; The amino acid sequence of the phenylalanine hydroxylase is shown in SEQ ID No.

1.

2. The phenylalanine hydroxylase mutant according to claim 1, It is characterized in that When there are four point mutations at the same time, the point mutation positions include: K58G, Q117K, K230R and C265S.

3. A recombinant strain pET28a-PAH / BL21, It is characterized in that Constructed by the following construction methods: Connecting the gene encoding the phenylalanine hydroxylase mutant according to claim 1 or 2 into pET-28a to obtain a recombinant vector; The obtained recombinant vector was transformed into Escherichia coli BL21 to obtain the recombinant strain pET28a-PAH / BL21.

4. A method for preparing 5-hydroxytryptophan, It is characterized in that The following steps are involved: 1) fermenting the recombinant strain pET28a-PAH / BL21 according to claim 3 and collecting the cells; 2) The bacterial cells obtained in step 1) are mixed with water and tryptophan and then transformed to obtain 5-hydroxytryptophan.

5. The preparation method according to claim 4, It is characterized in that The culture medium used in the fermentation in step 1) includes: 10 g / L glucose, 11.5 g / L yeast extract, 15 g / L peptone, 4 g / L ammonium sulfate, 18 g / L dipotassium hydrogen phosphate, 3 g / L potassium dihydrogen phosphate and 1.2 g / L magnesium sulfate, pH 7.0; The fermentation conditions include: a rotation speed of 170 rpm, culturing at 37° C. for 6 hours, adding isopropyl-β-D-thiogalactoside with a final concentration of 0.2 mM when the OD value reaches 0.6-0.8, and inducing expression at a temperature of 28° C. and 140 rpm for 20-28 hours.

6. The preparation method according to claim 4, It is characterized in that In step 2), the mass ratio of the bacteria to water and tryptophan is 10:100:0.2; The transformation conditions include: temperature of 37° C. and time of 24 h.

7. A method for preparing 5-hydroxytryptophan, It is characterized in that The following steps are involved: A. mixing an enzyme solution containing the phenylalanine hydroxylase mutant according to claim 1 or 2 with a resin, and obtaining an immobilized enzyme after solid-liquid separation; B. mixing the immobilized enzyme obtained in step A with tryptophan and tetrahydrobiopterin to obtain a reaction system; C. reacting the reaction system obtained in step B to obtain 5-hydroxytryptophan.

8. The method according to claim 7, It is characterized in that The enzyme activity concentration of the phenylalanine hydroxylase mutant in the enzyme solution of step A is 1350u / L; The mass ratio of enzyme activity in the enzyme solution to resin is 300U:1g, and the salt concentration of the enzyme solution is 1.2M; The resin includes epoxy resin and / or amino resin. The model of the epoxy resin is ES-103B, and the model of the amino resin is ENK.

9. The method according to claim 7, It is characterized in that In the reaction system of step B, the concentration of the immobilized enzyme is 2.6 g / L, the concentration of tryptophan is 2 g / L, and the concentration of tetrahydrobiopterin is 0.01 g / L; The pH value of the reaction system is 8.

3.

10. The method according to claim 7, It is characterized in that The reaction conditions of step C include: temperature of 13° C. and reaction time of 1 h.